STAT+: Pharmalittle: FDA approves a medicine to combat ALS; Medicare drug-price talks are poised to become a legal battle
And so, another working week will soon draw to a close. Not a moment too…
Author: STAT
Opinion: How the Inflation Reduction Act can help decarbonize the health care industry
The climate crisis — the greatest threat to human health in history — is often…
Fungi find their way into cancer tumors, but what they’re doing there is a mystery
For a while, scientists thought the trillions of microbes on our bodies lived in landscapes…
Opinion: Maternal-fetal surgery is not an alternative to abortion care
Every day, pregnant people across the United States get the news that the futures they…
Who will get the call from Stockholm? It’s time for STAT’s 2022 Nobel Prize predictions
We live in a time where the rate of medical and superlative scientific advances is…
STAT+: The biotech scorecard for the fourth quarter: 13 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth…
FDA approves ALS drug from Amylyx, giving patients a much-needed treatment option
The Food and Drug Administration approved a new medicine for ALS from Amylyx Pharmaceuticals on…
FDA moves on AI tools, bionic pancreas research, & equity in digital therapeutics
You’re reading the web edition of STAT Health Tech, our guide to how tech is…
Juul exec slams FDA over its approach to regulating vaping
WASHINGTON — A Juul executive fiercely criticized the Food and Drug Administration’s approach toward regulating…
Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy
Does the latest Alzheimer’s disease drug actually work? When does the FDA call in security?…
STAT+: Health app companies wrestle with how to design studies to prove treatments work
For companies that have spent years developing interactive technologies to help treat disease, the tricky…
STAT+: With rivals on its heels, Illumina launches a new line of high-end DNA sequencers
SAN DIEGO — After a steep drop in its stock price and with mounting competition…
STAT+: Pharmalittle: Medicare plans sizable infrastructure for negotiating drug prices; Alzheimer’s data also boost Roche and Lilly
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Medicare lays out the bureaucracy it will need to negotiate drug prices
WASHINGTON — New documents obtained by STAT outline how Medicare is planning to build out…
Opinion: Rabies will continue to take lives without stronger human-animal health policies
The Covid-19 pandemic set back many of the global health goals for 2030. One of…
Ebola experimental vaccine trial may begin soon in Uganda
A clinical trial of one or perhaps two experimental vaccines designed to protect against the Ebola…
Opinion: How health systems can truly value Black lives: help close the racial wealth gap
Institutional declarations of support for Black lives were ubiquitous in the aftermath of the murder…
Her mother’s abortion was required under China’s one-child policy. Her own would be illegal under Tennessee’s post-Roe ban
This is part of a series of snapshots from post-Roe America. It started as a…
STAT+: Burning questions left unanswered about the latest Alzheimer’s therapy
News of the first clearly successful clinical trial for a new Alzheimer’s disease treatment in…
A bionic pancreas aims to take the math out of managing type 1 diabetes
For people living with type 1 diabetes, it pays to be good at math. Keeping…
FDA proposes new rules for which foods can be called ‘healthy’
The Food and Drug Administration wants to update its rules for which foods can be…
Early analysis suggests monkeypox vaccine is reducing risk of infection in U.S.
A very preliminary analysis of data from 32 states appears to suggest that the monkeypox…
An Alzheimer’s therapy scores winning results, but what could it mean for patients?
The news Tuesday night that a clinical trial of an experimental Alzheimer’s therapy had succeeded…
STAT+: A ‘disaster’, or a ‘clear path’ forward?: New FDA guidance on AI in medicine sparks strong reactions
New guidance from the Food and Drug Administration is triggering strong reaction from researchers and…
STAT+: If a new Alzheimer’s drug works, was there any point to the Aduhelm controversy? Yes
The announcement Tuesday night from Eisai and Biogen that their experimental medicine, lecanemab, reduced Alzheimer’s…
Virtual drug screening identifies possible new antidepressants in LSD-like molecules
What’s a hallucinogen without the hallucinations? Perhaps a potent and fast-acting antidepressant, according to a…
STAT+: Pharmalittle: Biogen Alzheimer’s drug slowed cognitive decline in a trial; European pharma warns energy costs may halt some generic production
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Virtual Event: When the Barrier to a Breakthrough Drug Is You Can’t Make It
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Lilly is accused by the federal government of discriminating against older sales reps
In an unusual move, the U.S. Equal Employment Opportunity Commission has filed a lawsuit accusing…
Opinion: Medicare needs to cover the full spectrum of care for substance use disorders
Imagine if Medicare covered treatments for stage 1 or stage 4 cancers, but nothing in…
Where caregiving is a family affair, Alzheimer’s places a heavy burden on children and spouses
HARLINGEN, Texas — Here in the Rio Grande Valley almost everyone knows, or cares for,…
Opinion: Listen: How the Dobbs decision could affect how and where clinical trials are conducted
The Supreme Court’s decision to overturn Roe v. Wade opened the door to allow states…
On the Texas-Mexico border, a bold plan to diversify Alzheimer’s research takes shape
BROWNSVILLE, Texas — Gladys Maestre is on a scouting mission. The Alzheimer’s disease researcher is…
Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial
An investigational Alzheimer’s disease treatment from Biogen and Eisai slowed the rate of cognitive decline…
In new guidance, FDA says AI tools to warn of sepsis should be regulated as devices
The U.S. Food and Drug Administration on Tuesday published a list of artificial intelligence tools…
Google’s hospital play, Optum’s data shakeup, & the call for more telehealth oversight
You’re reading the web edition of STAT Health Tech, our guide to how tech is…
STAT+: Top FDA official acknowledges agency’s slow process for reviewing health app updates
The Food and Drug Administration’s approach to reviewing updates to software products is far slower…
New study sees possible link between aluminum in childhood vaccines and risk of asthma, but caveats abound
A new study suggests there may be a link between aluminum used in vaccines that…
Health funding battles, a nutrition policy overhaul, and two CBD developments
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: Democrats concede on passing ‘clean’ FDA funding bill; Biogen whistleblower nets $250 million
Good morning, one and all. Damian here, filling in for Ed Silverman once more. Here…
Opinion: The Inflation Reduction Act will help the U.S. achieve maximum vaccine access and uptake, but access gaps remain
One of the many achievements in the Inflation Reduction Act (IRA), which President Biden signed…
Opinion: Doctors who knowingly spread Covid-19 lies should be held accountable
The California State Legislature has sent a bill to Gov. Gavin Newsom that strengthens discipline…
‘It is sinking us even further’: STI clinics, already stretched thin, strain under weight of monkeypox response
At the Los Angeles LGBT Center’s sexual health clinic, patients are normally seen within 24…
STAT+: Google and Fitbit launch new cloud tools to help hospitals use wearables
Google Cloud and Fitbit are rolling out a new offering they hope will ease some…
STAT+: Democrats concede to clean user fee agreement to fund FDA
WASHINGTON — Democrats have conceded to Republican demands and agreed to fund the Food and…
Medicare Advantage boosterism, providers’ surprise billing savior in Texas, and a health insurance firewall
You’re reading the web edition of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: GSK picks its first female CFO; Pfizer advances Omicron booster for kids
Good morning, everyone. Damian Garde here, filling in for Ed Silverman at the outset of…
Opinion: FDA: Ignore a pharma company’s deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug
In an effort to sway the Food and Drug Administration not to withdraw accelerated approval…
STAT+: Health insurers are painting a misleading picture of Medicare Advantage savings, experts say
The health insurance industry is continuing its campaign to convince the public that Medicare Advantage…
Opinion: Subject, not suspect: The new hazards of conducting clinical research in the Dobbs era
Here’s a scenario anyone who has done clinical research will recognize: A 32-year-old woman participating…